At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 792 enrolled
Drug / intervention
Dexamethasone +2 moredrug
Likely dose
Dexamethasone 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
In Brief
A Phase 3 clinical trial evaluating Dexamethasone, Lenalidomide, and 1 other intervention for Relapsed Multiple Myeloma. Completed, enrolled 792 participants across 127 sites in 20 countries.
Detailed Summary
The primary objective was to compare progression-free survival in adults with relapsed multiple myeloma who are receiving CRd vs participants receiving Rd in a randomized multicenter setting.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsed Multiple Myeloma
CountriesAustria, Belgium, Bulgaria, Canada, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, Poland, Romania, Russia, Serbia, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2010
Enrollment StartJul 2010
Primary CompletionJun 2014
Study CompletionDec 2017
TodayJul 2026
First PostedMar 4, 2010
Enrollment StartJul 14, 2010
Primary CompletionJun 16, 2014
Study CompletionDec 5, 2017
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 16.3 years ago
Interventions
Dexamethasonedrug
40 mg orally or IV on days 1, 8, 15, 22
Lenalidomidedrug
25 mg orally on days 1-21
Carfilzomibdrug
20 mg/m², 27 mg/m² intravenously